IFLScience needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time.

ACDN-01 is under clinical development by Ascidian Therapeutics and currently in Phase II for Retinopathy. According to GlobalData, Phase II drugs for Retinopathy have a 51% phase transition success ...

ACDN-01 is under clinical development by Ascidian Therapeutics and currently in Phase II for Juvenile Macular Degeneration (Stargardt Disease). According to GlobalData, Phase II drugs for Juvenile ...